MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
3:55 PM | Friday | Sep 4, 2026 The Motley Fool

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

News Thumbnail
5:30 PM | Thursday | Sep 3, 2026 The Motley Fool

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

News Thumbnail
5:22 PM | Thursday | Sep 3, 2026 FXEmpire

Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets

News Thumbnail
1:26 PM | Thursday | Sep 3, 2026 Zacks Investment Research

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

News Thumbnail
11:10 AM | Thursday | Sep 3, 2026 Barrons

Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating

News Thumbnail
11:10 AM | Thursday | Sep 3, 2026 The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

News Thumbnail
8:05 AM | Thursday | Sep 3, 2026 247 Wallst

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

News Thumbnail
6:36 AM | Thursday | Sep 3, 2026 Seeking Alpha

Moderna: Massive Asymmetry About What The mRNA Is!

News Thumbnail
11:10 AM | Thursday | Sep 3, 2026 The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

News Thumbnail
11:10 AM | Thursday | Sep 3, 2026 Barrons

Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating

News Thumbnail
8:05 AM | Thursday | Sep 3, 2026 247 Wallst

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

News Thumbnail
6:36 AM | Thursday | Sep 3, 2026 Seeking Alpha

Moderna: Massive Asymmetry About What The mRNA Is!

News Thumbnail
12:04 PM | Wednesday | Sep 2, 2026 ETF Trends

Why Moderna's Cancer Vaccine Matters to Investors

News Thumbnail
11:31 AM | Tuesday | Sep 1, 2026 Zacks Investment Research

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

News Thumbnail
7:00 AM | Tuesday | Sep 1, 2026 Accesswire

Moderna to Present at Upcoming Conferences in September 2026

News Thumbnail
3:50 AM | Tuesday | Sep 1, 2026 The Motley Fool

Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?

News Thumbnail
4:13 AM | Monday | Aug 31, 2026 Defense World

Alyeska Investment Group L.P. Trims Stake in Moderna, Inc. $MRNA

News Thumbnail
2:45 AM | Monday | Aug 31, 2026 Defense World

Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of “Hold” by Brokerages

News Thumbnail

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

The Motley Fool

3:55 PM | Friday | Sep 4, 2026

news photo
Loading...

Moderna's shares have pulled back since their most recent highs. The biotech's latest clinical milestone makes its prospects far more attractive.

Read full article redirect
3:55 PM | Friday | Sep 4, 2026

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

The Motley Fool

Moderna's shares have pulled back since their most recent highs. The biotech's latest clinical milestone makes its prospects far more attractive.

Read full article arrow
News Thumbnail
5:30 PM | Thursday | Sep 3, 2026

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

The Motley Fool

BioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines. Both have attractive pipelines that could lead to important new approvals over the next few years.

Read full article arrow
News Thumbnail
5:22 PM | Thursday | Sep 3, 2026

Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets

FXEmpire

Moderna consolidates after a dramatic breakout, with a bullish pennant forming near resistance and offering a potential signal for another powerful advance.

Read full article arrow
News Thumbnail
1:26 PM | Thursday | Sep 3, 2026

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

Zacks Investment Research

MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.

Read full article arrow
News Thumbnail
11:10 AM | Thursday | Sep 3, 2026

Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating

Barrons

Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

Read full article arrow
News Thumbnail
11:10 AM | Thursday | Sep 3, 2026

3 Stocks Whose Competitive Walls Tower Over Nvidia's

The Motley Fool

Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.

Read full article arrow
News Thumbnail
8:05 AM | Thursday | Sep 3, 2026

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

247 Wallst

Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.

Read full article arrow
News Thumbnail
6:36 AM | Thursday | Sep 3, 2026

Moderna: Massive Asymmetry About What The mRNA Is!

Seeking Alpha

Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA's upside hinges on Intismeran's ability to scale across multiple tumor types, not just melanoma. The 50/50 partnership with Merck provides both distribution strength and shared economics for Intismeran.

Read full article arrow
News Thumbnail
11:10 AM | Thursday | Sep 3, 2026

3 Stocks Whose Competitive Walls Tower Over Nvidia's

The Motley Fool

Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.

Read full article arrow
News Thumbnail
11:10 AM | Thursday | Sep 3, 2026

Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating

Barrons

Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

Read full article arrow
News Thumbnail
8:05 AM | Thursday | Sep 3, 2026

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

247 Wallst

Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.

Read full article arrow
News Thumbnail
6:36 AM | Thursday | Sep 3, 2026

Moderna: Massive Asymmetry About What The mRNA Is!

Seeking Alpha

Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA's upside hinges on Intismeran's ability to scale across multiple tumor types, not just melanoma. The 50/50 partnership with Merck provides both distribution strength and shared economics for Intismeran.

Read full article arrow
News Thumbnail
12:04 PM | Wednesday | Sep 2, 2026

Why Moderna's Cancer Vaccine Matters to Investors

ETF Trends

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

Read full article arrow
News Thumbnail
11:31 AM | Tuesday | Sep 1, 2026

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Zacks Investment Research

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | Sep 1, 2026

Moderna to Present at Upcoming Conferences in September 2026

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m.

Read full article arrow
News Thumbnail
3:50 AM | Tuesday | Sep 1, 2026

Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?

The Motley Fool

Moderna and Merck recently announced positive results from a late-stage clinical study of their melanoma treatment. In recent years, Moderna has broadened its reach beyond its first product: the coronavirus vaccine.

Read full article arrow
News Thumbnail
4:13 AM | Monday | Aug 31, 2026

Alyeska Investment Group L.P. Trims Stake in Moderna, Inc. $MRNA

Defense World

Alyeska Investment Group L.P. cut its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 86.2% during the undefined quarter, according to its most recent Form 13F filing with the SEC.
The institutional investor owned 560,819 shares of the company's stock after selling 3,490,366 shares during the period. Alyeska Investment Group L.P. owned

Read full article arrow
News Thumbnail
2:45 AM | Monday | Aug 31, 2026

Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of “Hold” by Brokerages

Defense World

Shares of Moderna, Inc. (NASDAQ: MRNA - Get Free Report) have received an average rating of "Hold" from the twenty-three research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and seven have issued a buy recommendation

Read full article arrow
News Thumbnail